Novo Nordisk On The Pluses And Minuses Of The UK Post-Brexit R&D Environment
R&D Good But Batch-Testing Accord And Medicines Uptake Concern
Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.
You may also be interested in...
Life science SMEs and their investors need to comply with new UK government checks on their dealmaking.
Mikaela Odlander, one of In Vivo’s 2021 Rising Leaders, was appointed director of digital therapeutics at Orexo in November 2019. The newly formed digital therapeutics (DTx) arm of the Swedish pharma and digital health company entered the American health care landscape in 2020 with two new products that address substance abuse and mental health problems.
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.